Myomo opened lower at $1.24, compared with its previous close of $1.25. In the last trading session, the stock traded between $1.20 and $1.26. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Myomo is now worth
$ 12.63
Resulting in a loss of
$ 87.37 (87.37%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.04 (-3.28%)
Day High
$1.26
Day Low
$1.20
Day Open
$1.24
Prev Close
$1.25
Volume
1,76,226
1W Return
-6.57%
1M Return
-12.07%
3M Return
-19.67%
6M Return
42.24%
1Y Return
42.24%
Market Cap ($ Mn)
48
PE Ratio
-
PB Ratio
10.85
PEG Ratio
-
ROE
-86.48%
ROCE
-50.99%
EPS (TTM)
$-0.11
1 Week
-6.57%
1 Month
-12.07%
3 Months
-19.67%
6 Months
42.24%
9 Months
50.67%
Myomo Q3FY26 Results: Revenue up 22% to $12.3M, gross margin hits 71.3%
Revenue rose 22% YoY to $12.3 million, beating consensus estimates. Gross margin expanded 750 bps to 71.3% driven by higher ASP and cost efficiencies. Recurring patient sources contributed 54% of revenue, up from 33% YoY. Adjusted EBITDA reached breakeven, improving from a $2.7 million loss last year. Full-year guidance narrowed to $46-47 million; GAAP loss remains at $0.10 per share.
3 days agoMyomo Q2FY26 Results: Revenue up 21%, guidance raised to $45-47 million
Revenue rose 21% YoY to $11.7 million, driven by higher ASP and unit volume. Recurring patient sources now comprise 53% of revenue, up from 26% a year ago. Operating expenses grew less than 1%, narrowing operating loss to $2.3 million. Full-year revenue guidance raised to $45-47 million from previous $43-46 million. Cash used in operations improved to $1.9 million from $8.9 million in prior year.
1mo agoAscendiant Capital raises Myomo price target to $10.5, maintains Buy
Ascendiant Capital raises Myomo price target from $10 to $10.5. Analyst Edward Woo maintains a Buy rating on the stock. No operational metrics or financial results disclosed in update.
2mo agoMyomo raises FY26 sales guidance to $45-47 million range
Myomo raises FY2026 sales guidance to $45.000 million-$47.000 million from $43.000 million-$46.000 million, surpassing the $44.434 million estimate. The revision reflects strong demand for its neuromuscular devices.
3mo agoMyomo Q3 Results: Sales guidance beats analyst estimates
Myomo forecasts Q3 sales of $11.500M-$12.000M, beating the $11.168M estimate. This suggests strong product demand and effective market execution for the neuromuscular stimulation device maker.
3mo agoMyomo to present at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
Myomo, Inc. announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, set for June 23–24. CEO Paul Gudonis and CFO David Henry will present and meet with investors to discuss the company's wearable medical robotics solutions. The presentation will be webcast live, with a replay available afterward.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Myomo is now worth
$ 12.63
Resulting in a loss of
$ 87.37 (87.37%)
Note: Past profits do not guarantee future returns.
